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Abstract 
Obesity and metabolic syndrome are associated with several cancers, however, the molecular 
mechanisms remain to be fully elucidated. Recent studies suggest that hypercholesterolemia 
increases intratumoral androgen signaling in prostate cancer, but it is unclear whether androgen-
independent mechanisms also exist. Since hypercholesterolemia is associated with advanced, 
castrate-resistant prostate cancer, in this study, we aimed to determine whether and how 
hypercholesterolemia affects prostate cancer progression in the absence of androgen signaling.  
We demonstrate that diet-induced hypercholesterolemia promotes orthotopic xenograft PC-3 cell 
metastasis, concomitant with elevated expression of caveolin-1 and IQGAP1 in xenograft tumor 
tissues. In vitro cholesterol treatment of PC-3 cells stimulated migration and increased IQGAP1 
and caveolin-1 protein level and localization to a detergent-resistant fraction. Down-regulation of 
caveolin-1 or IQGAP1 in PC-3 cells reduced migration and invasion in vitro, and 
hypercholesterolemia-induced metastasis in vivo. Double knock-down of caveolin-1 and 
IQGAP1 showed no additive effect, suggesting that caveolin-1 and IQGAP1 act via the same 
pathway. Taken together, our data show that hypercholesterolemia promotes prostate cancer 
metastasis independent of the androgen pathway, in part by increasing IQGAP1 and caveolin-1. 
These results have broader implications for managing metastasis of cancers in general as 
IQGAP1 and hypercholesterolemia are implicated in the progression of several cancers. 
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Introduction 
Epidemiological studies have long reported an association between hypercholesterolemia, 
obesity and several types of cancers, with cholesterol-lowering drugs showing clinical benefit in 
the prevention and delay of prostate cancer progression [1, 2]. Recent studies have begun to 
reveal the potential mechanisms by which the cholesterol biosynthetic pathway and its 
metabolites impact carcinogenesis [3-6]. Elevated blood cholesterol levels may enhance the 
androgen receptor pathway via intratumoral de novo androgen synthesis in the prostate, 
contributing to prostate cancer progression [7]. The cholesterol metabolite 27-hydroxycholesterol 
increases estrogen receptor function in breast cancer [4, 5], while oxidized cholesterol 
metabolites (oxysterols) released from tumor cells promote angiogenesis and 
immunosuppression in the tumor microenvironment [8].   
 
 In addition to its role in steroid hormone synthesis and function, cholesterol is an 
essential structural component of mammalian membranes. Cholesterol-enriched membrane 
microdomains, also termed lipid rafts, are reported to regulate a myriad of cellular functions [9]. 
Previous studies suggest a potential role for membrane cholesterol [10]. and the cholesterol-
binding membrane protein, caveolin-1, in promoting prostate cancer progression [11]. Elevation 
of lipid profiles, including cholesterol, is a common side effect of androgen deprivation therapy 
for advanced prostate cancer [12]. Given the association of hypercholesterolemia with advanced, 
castrate-resistant prostate cancer which is insensitive to androgen pathway blockade [13]. it is 
important to determine whether high circulating and cellular cholesterol can directly affect 
advanced prostate cancer progression in the absence of androgen signaling. 
 
In this study, we examined the effects of diet-induced hypercholesterolemia on androgen-
receptor negative prostate cancer progression, and investigated the potential mechanisms. We 
show that diet-induced hypercholesterolemia accelerated secondary tumor metastases to lymph 
node, lung and bones in orthotopic xenograft mice using androgen receptor negative PC-3 cells. 
Ras GTPase-activating-like protein IQGAP1 was identified and validated as a 
hypercholesterolemia-induced metastasis-associated protein. Moreover, we show that 
knockdown of IQGAP1 or caveolin-1 in PC-3 cells abolished the hypercholesterolemia-induced 
metastasis from xenografts, indicative of their functional involvement in prostate cancer 
metastasis in vivo. IQGAP1 is a membrane-cytoskeleton scaffolding protein implicated in the 
progression of several types of tumors, potentially by regulating the Ras-MAP kinase and rac-
cdc42 pathways [14-16]. Recruitment of IQGAP1 to plasma membrane ruffles facilitates cell 
migration [15]. however, a role for cholesterol-enriched membranes in IQGAP1 regulation has 
not been examined.  
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Results 
Diet-induced hypercholesterolemia accelerates xenografted tumor metastasis 
To determine the direct but androgen-independent effects of hypercholesterolemia on advanced 
prostate cancer progression, we used an androgen-receptor negative prostate cancer cell line PC-
3, expressing the luciferase gene (Supplementary Figure S1) in an orthotopic xenograft mouse 
model. Male NOD/SCID mice were randomly assigned to low-cholesterol normal (LC-D) and 
isocaloric hypercholesterolemic diet (HC-D) groups. Two weeks after diet initiation, in vivo and 
ex vivo studies were performed as illustrated in Figure 1a. Similar to previous studies [7, 10]. 
serum cholesterol levels (Figure 1b) but not body weights (Figure 1c) were significantly 
increased in the HC-D group. However, the intensity of in vivo bioluminescence (p = 0.87, 
Figure 1d and 1e) and final prostate tumor weights (p = 0.23, Figure 1f) were not significantly 
different between the groups, although the HC-D group showed an increased trend. 
 
Ex vivo bioluminescence imaging was used to assess metastasis from the xenograft 
tumors [17]. Previous studies have reported PC-3 metastases including microscopic lung and 
bone metastases [18, 19]. The HC-D group showed higher bioluminescence intensity in the para-
aortic lymph node (p = 0.0007, Figure 1g), mesenteric lymph node (p = 0.0021, Figure 1h) and 
the lung (p = 0.0275, Figure 1i). Bone metastasis is the major cause of prostate cancer related 
death[20] and previous studies have reported microscopic bone metastases from PC-3 xenograft 
tumors [18]. Indeed, 42% of bones collected from the LC-D group showed ex vivo positive 
bioluminescence (Figure 1j). Consistent with lymph node and lung metastases, an increased 
number of bones demonstrated positive bioluminescence in mice in the HC-D group in both the 
front (p = 0.0036) and rear legs (p = 0.0014, Figure 1j). Lymph node metastases and microscopic 
metastases of lung and bone marrow as well as metastasis in joint tissues were confirmed by 
histopathology (Supplementary Figure S2). Taken together, these results demonstrate that diet-
induced hypercholesterolemia increased PC-3 tumor metastasis but not primary tumor growth. 
 
Diet-induced hypercholesterolemia is associated with increased IQGAP1 and caveolin-1 in 
the tumor 
Metastatic prostate cancer is one of the most common causes of cancer-related death in men [21]. 
To identify the molecular mechanism which mediates hypercholesterolemia-stimulated prostate 
cancer metastasis, we first evaluated angiogenesis and hormone receptor signaling, based on 
recent reports [3-6, 8, 22]. Tumor angiogenesis and lymphangiogenesis were examined by 
staining primary tumor sections with the panendothelial cell marker endomucin and the 
lymphatic specific marker podoplanin (Figure 2a). No significant difference in angiogenesis 
(Figure 2a and 2b) or lymphangiogenesis (Figure 2a and 2c) was observed. While PC-3 cells lack 
androgen receptor expression, it was possible that hypercholesterolemia increased circulating 
testosterone levels which could positively affect tumor stroma tissues. Hence we measured 
serum testosterone levels (Figure 2d). Surprisingly, serum testosterone levels were significantly 
decreased in both diet groups at the conclusion of the experiment (p = 0.016 in LC-D and p < 
0.0001 in HC-D, Figure 2d) which might be due to aggressive invading tumor cells from the 
primary and secondary tumors to the testis and surrounding organs/tissues (Figure 2e and 
Supplementary Figure S3). Additionally, hypercholesterolemia was associated with a greater 
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reduction in circulating testosterone levels, possibly due to negative feedback in impaired 
testicular functions [23, 24]. 
 
To identify metastasis-promoting proteins induced by cholesterol, we performed in vitro 
quantitative proteomics using stable isotope labeling by amino acids in cell culture (SILAC). 
Initial experiments showed that long-term growth of cell culture in reduced-cholesterol media 
affected cell proliferation, anchorage-independent growth, as well as migration (Supplementary 
Figure S4). To mimic the in vivo results of increased metastasis but not primary tumor growth, 
we selected short-term, 5 hour treatment which increased PC-3 transmigration (Figure 3a) but 
not proliferation (Figure 3b). Therefore, SILAC was performed according to the scheme in 
Figure 3c. 
 
Compared to cells maintained in cholesterol-deficient medium (CDM) containing 5% 
delipidated fetal bovine serum (FBS), incubation with additional 5 µM cholesterol for 5 hours 
significantly altered total cellular cholesterol level (Figure 3d) but not total cellular protein 
amount (Figure 3e). Liquid chromatography-tandem mass spectrometry and database searching 
identified and quantified a total of 441 of proteins from 3 biological replicates. Significance of 
SILAC ratios was determined by permutation test [25-27]. By applying a 1.5 fold change filter 
for biological significance, 31 proteins were deemed to be significantly altered by cholesterol 
supplementation (Figure 3f and, Supplementary Table S1 and S2). The top ten proteins up-
regulated by short-term cholesterol treatment included Ras GTPase-activating-like protein 
IQGAP1 (Figure 3g), a protein implicated in tumor metastasis in several cancers [16]. IQGAP1 
is a scaffolding protein which interacts with Rac1 and Cdc42, promoting actin polymerization at 
the leading edge of migrating cells [28]. As there are no reports linking hypercholesterolemia or 
prostate cancer with IQGAP1, we went on to confirm this result in vitro and in vivo. In parallel 
with IQGAP1, we also measured the level of caveolin-1 as it is associated with metastasis and 
poor prognosis in prostate cancer [19, 29] and has been functionally linked with IQGAP1[30-
32]. 
 
We performed Western blotting of both xenograft tumor and cell lysates to determine the 
effect of hypercholesterolemia on the expression of level of caveolin-1 and IQGAP1. 
Interestingly, xenograft tumor lysates from the HC-D group showed higher expression of both 
IQGAP1 (2.85 ± 0.50, p = 0.003) and caveolin-1 (3.0 ± 0.7, p = 0.011, Figure 3h), although 
cholesterol treatment of PC-3 cells in vitro increased expression of IQGAP1 but not caveolin-1 
(Figure 3i). Cholesterol elevation in the tumor was confirmed (Figure 3j). The differences 
between in vivo and in vitro data may relate to the different duration of hypercholesterolemia, 
presence of stromal cells, tissue architecture and/or feedback mechanisms in vivo. 
 
Cholesterol and caveolin-1 recruit IQGAP1 to lipid organized membrane microdomains 
Having established IQGAP1 as a cholesterol-induced protein in PC-3 cells, we next examined its 
expression in other commonly-used prostate cancer cell lines (Figure 4a). In agreement with a 
role in mediating metastasis, the level of IQGAP1 is higher in aggressive prostate cancer cells, 
PC-3 and DU145, which also express caveolin-1 (Figure 4a). Compared to PC-3 cells (Figure 
3i), caveolin-1-negative LNCaP cells showed a delay in time-response of cholesterol-induced 
IQGAP1 elevation, which was significant at 20 hours but not at 5 hours post cholesterol addition 
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(Supplementary Figure S5). These results suggest an association between cholesterol-sensitivity 
and aggressiveness of prostate cancer cell lines, with IQGAP1 being a potential downstream 
effector. 
 
Cholesterol regulates gene expression via two transcription factors, sterol regulatory 
element binding protein (SREBP) and liver X receptor (LXR). Hence, we tested the hypothesis 
that hypercholesterolemia increases IQGAP1 protein at the transcriptional level using qPCR. 
Surprisingly, IQGAP1 mRNA was not responsive to cholesterol or oxysterol treatment in PC-3 
and LNCaP cells (Figure 4b and Supplementary Figure S6), indicating that hypercholesterolemia 
increases IQGAP1 protein at a post-transcriptional level. 
 
Next, we investigated if hypercholesterolemia altered membrane localization of IQGAP1, 
which mediates cell migration [15]. Dynamic membrane re-organization occurs during cell 
migration and is regulated by caveolin-1 via cholesterol-rich membranes (also called lipid rafts), 
partly through its role as the structural protein of plasma membrane pits caveolae [1, 30]. While 
IQGAP1 is known to enrich in membrane ruffles, association with cholesterol-rich membranes 
has not been examined. We evaluated the effect of cholesterol treatment on the localization of 
IQGAP1 in PC-3 cells (Figure 4c). IQGAP1 showed diffuse and punctate staining in control 
cells. After 20 hour treatment in cholesterol, we observed increasing localization of IQGAP1 to 
membrane ruffles (Figure 4c, arrows) which also stained with filipin, an antibiotic which stains 
cholesterol. These results suggest that cholesterol induced the translocation of IQGAP1 to 
cholesterol-rich membranes in the ruffles. To further investigate this, we employed a 
biochemical method of preparing cholesterol-rich membranes, previously established as 
detergent resistant fractions (DRFs) [33]. Caveolin-1 is a known membrane cholesterol-binding 
protein and served as a positive control for the fractionation (Figure 4d). IQGAP1 was 
alsodetected in PC-3 DRF. Both caveolin-1 and IQGAP1 levels in DRF were  increased by 
cholesterol treatment (Figure 4d).  
 
Previous studies suggest a functional interaction between caveolin-1 and IQGAP1 in 
regulating the ERK
 
[31] and integrin-linked kinase signaling pathways
 
[32]. Our results show 
that hypercholesterolemia increases the level of both proteins in the DRF fraction, but it is not 
clear whether caveolin-1 and IQGAP1 actually co-localize to the same membranes. To address 
this question, we performed immunofluorescence co-localization with and without cholesterol 
treatment (Figure 4e). Some co-localization was observed, but the effect of a 20 hour cholesterol 
treatment was minor (mean Pearson's R-values of 0.35 and 0.36 for control and cholesterol, 
respectively). In view of the previous publications on the functional interaction between 
caveolin-1 and IQGAP1 [31, 32], we also investigated if caveolin-1 is required for recruitment of 
IQGAP1 to DRF (Figure 4f).Interestingly, we observed a reduced level of DRF IQGAP1 in 
shCav1 PC-3 cells, while another cholesterol-rich membrane microdomain-associated protein, 
flotillin-1, was not affected (Figure 4f). These results suggest that caveolin-1 indirectly regulates 
IQGAP1-membrane association, potentially by modulating membrane lipid organization [34]. 
 
IQGAP1 and caveolin-1 facilitate PC-3 metastasis 
To further evaluate the involvement of IQGAP1 and caveolin-1 in PC-3 metastases in vivo, we 
performed hypercholesterolemic diet xenograft experiments using PC-3-luc cell lines with 
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reduced IQGAP1 and/or caveolin-1 expression. Firstly, pooled populations of shIQGAP1 and 
shCav1 PC-3 cells were established using lentiviral mediated shRNAs and flow cytometry 
(based on the bicistronic co-expression of GFP in the lentivirus). A double knockdown cell line 
was generated by infecting shIQGAP1 cells with shCav1 lentivirus. Reduced protein levels were 
confirmed by Western blotting (Figure 5a). Preliminary in vitro studies showed similar 
attenuation of transmigration and invasion between shIQGAP1, shCav1 and double knockdown 
cells compared to scrambled control (Figure 5b, 5c and Supplementary Figure S7). There was no 
difference in proliferation between the 4 cell lines (Figure 5d). Before in vivo study, the intensity 
and linearity of in vitro bioluminescence of PC-3-luc shIQGAP1 and shCav1 cell lines were 
confirmed for accurate comparison between groups (Supplementary Figure S8).  
 
A total of 42 male NOD/SCID mice were randomly assigned to and xenografted with 
scrambled control (Scr-Ctrl), IQGAP1 knockdown (shIQGAP1), caveolin-1 knockdown 
(shCav1) and double knockdown (shIQ+shCa) PC-3 cells. In vivo and ex vivo studies were 
performed as described in Figure 1a using HC-D. As expected, all groups showed similar body 
weight (p = 0.21, Supplementary Figure S9a) and serum cholesterol levels (p = 0.96, 
Supplementary Figure S9b). Whole body in vivo imaging showed similar primary tumor growth 
curves (p = 0.55, Figure 6a and 6b), and final prostate tumor weight also revealed no significant 
changes (p = 0.39, Figure 6c) between the groups. Tumor metastases were determined in lymph 
nodes, lung and bones including joint tissues. Measurement of lymph node size revealed 
significantly smaller lymph nodes in knockdown groups compared to control (p < 0.0005), but 
not among knockdown groups (p = 0.8809, Figure 6d). Similarly, ex vivo imaging demonstrated 
significantly reduced lymph node metastases (Figure 6e and 6f) as well as microscopic lung 
metastases (Figure 6e and 6g). Pairwise comparisons using Fisher’s exact test also demonstrated 
significantly reduced metastatic invasion to the bones and joints in shIQGAP1 (front limbs; p = 
0.0003, rear limbs; p = 0.0005), shCav1 (p = 0.012 and p = 0.0023, respectively), or double 
knockdown PC-3 cells (p = 0.0095 and p = 0.0012, respectively, Figure 6h). Double knockdown 
of IQGAP1 and caveolin-1 showed no additive effects in the reduction of metastases (Figure 6f, 
6g and 6h) suggesting action via the same molecular pathway. Taken together, these results 
suggest that IQGAP1 and caveolin-1 potentiate PC-3 metastasis, and that the elevation of 
IQGAP1 levels in hypercholesterolemia plays an important role in metastasis. 
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Discussion 
Androgen-deprivation therapy is the first line of treatment for advance prostate cancer. While 
highly effective in androgen-sensitive disease, resistance ultimately develops in most patients 
[13]. Androgen-deprivation therapy is associated with a spectrum of side effects, including 
elevated circulating cholesterol [12] which may paradoxically promote androgen-independent 
prostate cancer metastasis based on this study using a xenograft mouse model.  Our results 
indicate that in addition to the recently reported hormone receptor and cholesterol metabolism 
dependent mechanisms [3, 7] hypercholesterolemia per se can increase prostate cancer 
metastasis by modulating the properties of membrane microdomains. We further demonstrate the 
involvement of two proteins, caveolin-1 and IQGAP1 in hypercholesterolemia-induced xenograft 
tumor metastasis in vivo. Hence, caveolin-1, IQGAP1, or cholesterol-rich membrane 
microdomains (lipid rafts) are potential therapeutic targets for prevention or treatment of tumor 
metastasis. 
Caveolin-1 is a cholesterol binding protein well characterized by its role in formation of 
plasma membrane pits, caveolae [30]. Caveolin-1 has been considered a biomarker and 
therapeutic target in prostate cancer as it is released from prostate cancer cells, can be detected in 
the serum and positively associates with prostate cancer grade [29, 35, 36]. However, caveolin-1 
plays complex roles in cancer, with no existing models to explain its apparent contradictory 
tumor promoter and suppressor roles. Recent studies have begun to reveal the complexity of 
caveolin-1 function in cancer. Firstly, caveolin-1 may function pathologically outside caveolae 
via non-caveolar caveolin-1 membrane raft domain (caveolin-1 microdomains), as discovered in 
PC-3 cells [37] and validated in prostate cancer tissue samples [19]. While caveolin-1 
microdomains (not caveolae) are aberrantly induced in advanced prostate cancer cells, caveolae 
is reduced in the stroma during prostate cancer progression [19]. Given the complexity of 
caveolin-1 cellular and subcellular expression during cancer progression, therapeutic targeting of 
caveolin-1 is challenging. Furthermore, the molecular mechanisms of caveolin-1 in cancer 
progression have not been fully elucidated, although it likely involves modulation of lipid rafts 
and, based on the present data, IQGAP1. 
 
IQGAP1 is a ubiquitously expressed scaffolding protein that co-ordinates spatial 
signaling to regulate mitogenic, morphological and migratory processes [14]. Recent studies 
implicate a role for IQGAP1 in cancer, with overexpression reported in ovarian [38], liver [39], 
advanced colorectal [40], thyroid [41], pancreatic cancer [42] and squamous cell carcinoma [16]. 
Consistent with the known ubiquitous expression of IQGAP1, we detected it in all 4 commonly 
used prostate cancer cell lines (Figure 4a). Interestingly, IQGAP1 expression level correlated 
with aggressiveness of the cell lines, and shows correlation with caveolin-1, a known regulator of 
cholesterol membrane microdomains (Figure 4a). Furthermore, loss of caveolin-1 expression 
attenuated the level of IQGAP1 in the detergent resistant fraction (Figure 4f), indicative of 
caveolin-1-dependent recruitment to cholesterol-rich membrane domains. While IQGAP1 
membrane targeting is essential for its regulation of migration, to our knowledge, this is the first 
report of IQGAP1 targeting to cholesterol-rich membrane microdomains. Since cholesterol is 
essential for all cell types, and IQGAP1 is ubiquitously expressed, we asked if IQGAP1 targeting 
to cholesterol-rich lipid rafts can be detected in other cancer cells. By scrutinizing 66 mass 
spectrometry-based human lipid raft proteomics studies published between 2001 and 2013 using 
9 
 
RaftProt database [43], we found that IQGAP1 was identified in 12 experiments which included 
5 cancer cell lines, namely HeLa cervical  cancer, SW620 and SW480 colorectal cancer, NG108-
15 neuroblastoma-glioma hybrid, and Jurkat acute T cell leukemia [44-48]. Both detergent-based 
and detergent-free lipid raft extraction methods were featured in these experiments, indicating 
that the presence of IQGAP1 was not an isolation artifact. Furthermore, sensitivity to the 
cholesterol-depleting agent methyl-β-cyclodextrin suggests that IQGAP1 is a bona fide lipid raft 
protein.[48] Interestingly, lipid raft IQGAP1 level was elevated in a metastatic colorectal cancer 
cell line, compared to a non-metastatic cell line derived from the same patient [45]. On the other 
hand, CCL20 and cisplatin treatment did not affect lipid raft IQGAP1 levels in Jurkat cells [46, 
47]. Taken together, these data add support to our experimental results showing that IQGAP1 
targeting to lipid raft membranes can be regulated and may contribute to cancer metastasis. 
 
 In addition to IQGAP1, it is likely that other cholesterol-rich membrane microdomain-
associated proteins are altered by hypercholesterolemia to impact on tumor metastasis. Some 
examples include CD44, ezrin, uPAR and MMP-9 [49, 50]. This study adds alteration of 
cholesterol-rich microdomain composition and function to the increasing battery of molecular 
mechanisms linking hypercholesterolemia and cancer development and progression. Our results 
also highlight the importance of monitoring and maintaining low to normal blood cholesterol 
levels for prostate cancer patients, particularly those undergoing androgen deprivation therapy 
which can elevate cholesterol [12]. 
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Materials and Methods 
Cell lines 
Human prostate cancer cell lines PC-3 and LNCaP were purchased from American Type Culture 
Collection (ATCC). Human prostate cancer cell lines DU145, and PC-3 cells stably expressing 
firefly luciferase genes[51] were kindly provided by Dr. Ming-Tat Ling (Australian Prostate 
Cancer Research Centre–Queensland and Institute for Biomedical Health & Innovation, 
Queensland University of Technology, Translational Research Institute, Brisbane, Australia). 
The prostate cancer cell line 22Rv1 was kindly provided by Dr. John Hooper (Mater Medical 
Research Institute, Translational Research Institute, Brisbane, Australia). Prostate cancer cell 
lines were grown in RPMI-1640 medium (Invitrogen) supplemented with 5% fetal bovine serum 
(FBS). 
  
Reagents 
Xenolight D-luciferin potassium salt was obtained from ThermoFisher. Standard (low-
cholesterol) control diet and hypercholesterolemic diet (SF12-007, equivalent to TD88051, 
Harlan[10]) were purchased from Specialty Feeds (Glen Forrest, WA, Australia). Cholesterol 
levels were measured using Amplex Red cholesterol Assay Kit (Invitrogen), and fluorescence 
was measured by FLUOstar OPTIMA (BMG Labtech). Serum testosterone level was measured 
using homogeneous time resolved fluorescence based total testosterone assay kit (Cisbio) with a 
microplate reader, Artemis 101 (Cosmo Bio). Anti-caveolin-1 (610407) and anti-flotillin-1 
(610821) antibodies were from BD Transduction Laboratories, anti-IQGAP1 (22167-1-AP) from 
ProteinTech, anti-β-actin (A1978) from Sigma, anti-endomucin (sc-53941) from Santa Cruz 
Biotechnology and anti-podoplanin (RDI-103M40X) from Bioclone Aust. Alexa-fluor secondary 
antibodies were from Invitrogen.  
 
Orthotopic prostate cancer xenograft and monitoring mice 
Use of mice and all animal experiments described in this paper were conducted after prior 
approval by the University of Queensland Animal Ethics Committee (UQDI/326/10/AICR). 
Seven-week-old male NOD/SCID mice were purchased from the Animal Resource Centre 
(Canning Vale, WA, Australia), housed and maintained at the University of Queensland 
Biological Resource Animal Facility. 
All animal experiments including in vivo and ex vivo imaging were performed by two 
veterinarians as previously described.[19] Prior to xenograft experiments, the in vitro 
bioluminescence (BLI) sensitivity and linearity of PC-3-luciferase cell lines were confirmed 
(Supplementary Figures S1 and S8). Briefly, 2.5 x 10
5
 PC-3-luciferase cells were orthotopically 
injected into the dorsolateral prostate glands of male NOD/SCID mice under a dissecting 
microscope. Prior to in vivo bioluminescence imaging, D-luciferin dissolved in PBS was 
intraperitoneally injected, and then mice were anesthetized under isoflurane. At the end of the 
final experiments, mice were euthanized, and organs were collected in small 6 to 10 cm dishes in 
PBS for ex vivo imaging. All ex vivo imaging was finished within 15 minutes. The size of lymph 
nodes was measured using a caliper [tumor volume = (width)
2
 x length/2]. Mouse tissues were 
fixed in 10% neutral-buffered formalin for 24 hours, and bone tissues were decalcified in 10% 
EDTA for more than 2 weeks. Histopathological changes in mouse tissues were carefully 
examined by a veterinary pathologist. In order to examine serum cholesterol and testosterone 
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levels, retro-orbital sinus bleeding and cardiac puncture were used after diet restriction for 2 
hours. 
 
Angiogenesis and lymphangiogenesis 
Paraffin-embedded sections were used for staining with the panendothelial cell marker 
endomucin and the lymphatic specific marker podoplanin. The staining and quantification of the 
lymphatic and blood vessel densities for 5 randomly selected field for each slide was performed 
as described previously (n = 9 per each) [52]. Nuclei were stained using 4',6-Diamidino-2-
phenylindole dihydrochloride (DAPI). Slides were mounted on coverslips with 70% glycerol in 
PBS solution. 
 
Cholesterol-deficient medium and cholesterol loading in vitro 
To modulate cellular cholesterol levels in vitro, delipidated FBS and dialyzed FBS (control FBS) 
were used. Delipidated FBS was prepared by extracting lipids from FBS using diisopropylether 
and n-butanol in a ratio of 2:1. After centrifugation at 350 g for 15 minutes at 4
o
C, the 
supernatant was removed. FBS re-dissolved in diisopropylether in 1:1 ratio was centrifuged 
again at 250 g for 15 minutes at 4°C. Lastly, the supernatant was dialyzed against cold PBS 
using a 3500 MWCO dialysis membrane. Medium containing 5% delipidated FBS was used as 
cholesterol-deficient medium, and medium containing 5% dialyzed FBS without delipidation 
was used as control medium. Cholesterol (Sigma-Aldrich) was dissolved in ethanol, and 5 μM 
cholesterol or ethanol (vehicle) were added into cholesterol-deficient medium. 
 
In vitro quantitative proteomics using stable isotope labeling by amino acids in culture 
(SILAC) 
SILAC labeling of PC-3 cells was performed as previously described [25], with the following 
amino acids: “0/0” cells with normal isotopic Lys and Arg and “4/6” cells with 2H4-Lys and 
13
C6-
Arg. Greater than 99% incorporation was confirmed for the “4/6”-labelled cells by liquid 
chromatography tandem mass spectrometry (LC-MS/MS).  
After cholesterol treatment, cells were washed twice in PBS and scraped in PBS. Cell 
pellets were obtained by centrifugation at 220 g, then lysed in a modified RIPA buffer: 20 mM 
Tris pH 7.5, 150 mM NaCl, 0.5% Triton X-100, 0.5% sodium deoxycholate, 10 mM sodium 
fluoride, 0.5 mM sodium vanadate, 1 mM sodium pyrophosphate, 0.5 mM 4-(2-aminoethyl) 
benzenesulfonyl fluoride hydrochloride and protease inhibitors containing 1 μg/μL Aprotinin, 1 
μg/μL Antipain, 1 μg/μL Pepstatin, 1 μg/μL Leupeptin and 2.5 mM Benzamidine. Insoluble 
material was removed by pelleting at 12,000 g for 5 minutes at 4
o
C. The supernatant was 
collected as total cell lysate and the protein concentration was determined using Bradford assay 
(Biorad). 
 
In gel digest and tandem mass spectrometry 
Semi-automated in-gel tryptic digestion was performed on a liquid handler as previously 
described [53]. Peptides were analyzed using a 1200 Series nano high performance liquid 
chromatography coupled with Quadrupole-Time of Flight 6520 with a Chip-Cube interface 
(Agilent Technologies) as described [53]. Spectrum Mill (Agilent, B.04.00.127) was used for 
data analysis. Data were extracted with carbamidomethylated cysteine as a fixed modification 
and SILAC amino acids N-Lys, 
13
C6
15
N2-Lys, N-Arg and 
13
C6
15
N4-Arg as a mix modification. 
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Extracted data were searched against the SwissProt (release-2011_01) human database with the 
same modifications as above, and oxidized methionine as variable modifications. Precursor and 
product mass tolerance was set to ± 20 ppm and ± 50 ppm respectively. Reverse database scores 
were calculated with Spectrum Mill search engine by using the percentage of false positive 
identifications using the following cut-off: protein score > 11, peptide score >10 and scored peak 
intensity > 60%. All peptides identified had a global false discovery rate of less than 0.9%. Mean 
SILAC ratio (H/L) and standard deviations were calculated using all the peptide ratios matched 
to a protein, and p-values were calculated using peptide SILAC ratios as previously described 
[25-27]. 
 
Immunofluorescence 
Cells were grown on coverslips and fixed in 4% paraformaldehyde for 30min followed by three 
washes in PBS. Where stated, cells were stained with Filipin III (Sigma) at a concentration of 
50μg/ml in PBS for 2 hours followed by three washes in PBS. Cells were then permeabilized 
with 0.1% saponin and 5% BSA in PBS for 30min. Cells not stained with filipin were 
permeabilized in 0.1% Triton-X100 and 5% BSA in PBS for 30min, followed by 3 washes in 
PBS. The coverslips were incubated with the primary followed by secondary antibodies diluted 
in 3% BSA/PBS for 1hr each at room temperature. Coverslips were washed 3 times in PBS after 
the addition of each antibody. Where stated, coverslips were counterstained with 1μg/mL DAPI, 
washed three times with PBS, rinsed in MilliQ water and mounted in ProLong Diamond 
(Invitrogen). Cells were imaged by confocal microscopy (Ziess 510 Meta or Olympus FV1200). 
Pearson’s R value was calculated for 50 individual cells in ImageJ using the Coloc2 plugin. 
 
Generation of knockdown cell lines 
In order to knockdown caveolin-1 and/or IQGAP1 expression, lentiviral particles expressing 
shRNAs targeting IQGAP1 or caveolin-1 were obtained from the University of Queensland 
Institute for Molecular Bioscience, Life Science Automation Facility. The sequence of shRNAs 
for IQGAP1 was: shIQGAP1 (sIQ1), 
TGCTGTTGACAGTGAGCGATCCCACAAAGATGAAGTTGTATAGTGAAGCCACAGAT
GTATACAACTTCATCTTTGTGGGAGTGCCTACTGCCTCGGA; shIQGAP1 (sIQ2), 
TGCTGTTGACAGTGAGCGCAAGGTTGACTTCACAGAAGAATAGTGAAGCCACAGAT
GTATTCTTCTGTGAAGTCAACCTTTTGCCTACTGCCTCGGA; shIQGAP1 (sIQ3) 
TGCTGTTGACAGTGAGCGATCGAAGGTAGATCAGATTCAATAGTGAAGCCACAGAT
GTATTGAATCTGATCTACCTTCGACTGCCTACTGC CTCGGA. The sequence of 
shCaveolin-1 was: shCaveolin-1 (sC1), 
TGCTGTTGACAGTGAGCGAAACGATGACGTGGTCAAGATTTAGTGAAGCCACAGAT
GTAAATCTTGACCACGTCATCGTTGTGCCTACTGCCTCGGA; shCaveolin-1 (sC2), 
TGCTGTTGACAGTGAGCGCCACCACCTTCACTGTGACGAATAGTGAAGCCACAGATG
TATTCGTCACAGTGAAGGTGGTGATGCCTACTGCCTCGGA; shCaveolin-1 (sC3), 
TGCTGTTGACAGTGAGCGACACCTTCACTGTGACGAAATATAGTGAAGCCACAGAT
GTATATTTCGTCACAGTGAAGGTGGTGCCTACTGCCTCGGA. In preliminary studies, 
these different shRNAs were tested (Supplementary Figure 7a) with variable results. At least 2 of 
each shRNA construct (sIQ1, sIQ3; sC1, sC2) produced similar functional outcomes as measured 
by proliferation and transmigration assay (Supplementary Figure 7b, 7c).  Thereafter, sIQ3 and 
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sC2 were selected for producing double knockdown cells and for in vivo experiments (Figure 6, 
and shown in Figure 5 as representative). 
 
In vitro assays 
All in vitro studies were repeated at least three times. PC-3 proliferation was determined using 
Alamar Blue (Invitrogen). At appropriate time points after plating 10,000 cells in 96-well plates, 
cells were incubated in non-phenol red RPMI medium containing 10% Alamar Blue for 3 hours 
at 37
o
C. The fluorescence was measured using a microplate reader, FLUOstar OPTIMA (BMG 
LabTech).  
Transmigration assays were performed using 8 μm pore size transwell inserts (Corning) 
coated with collagen type I (Sigma-Aldrich) as previously described[54] with minor 
modification. Briefly 100 μl of cell suspension (2.5 x 106 cells per mL) in serum-free RPMI 
media containing 0.1% BSA was added into the upper chamber. RPMI media containing 5% 
FBS was added to the lower chamber and the PC-3 cells were allowed to migrate for 5 hours. 
The filter was rinsed in PBS and fixed in 4% paraformaldehyde. Cells that have not migrated 
were removed by swabbing the membrane from the top side of the insert. Cells remaining on the 
membrane were stained with haematoxylin. Matrigel invasion assay was performed similarly. 
Matrigel (BD Biosciences) was mixed 1:1 with medium, and the mixture was added into the 
transwell inserts. Then, 100 μl of cell suspension (5 x 106 cells per mL) in serum-free RPMI 
media containing 0.1% BSA was placed into the upper chamber, and then incubated at 37
o
C for 
20 hours. The number of migrated or invaded cells was counted in 5 different fields using a 
bright field microscope. 
 
Subcellular fractionation 
A detergent-resistant lipid-rich membrane fraction (DRF) was prepared as previously described 
[33], with minor modification. Briefly, PC-3 (1.5 x 10
6
) cells were plated in 10 cm dishes the day 
before harvest. Cell pellets were prepared by centrifugation at 220 g, and then homogenized in 
1% Triton-X-100, 25mM Tris HCl, pH 7.4, 150mM NaCl, 3mM EDTA and protease inhibitors 
by passage through a 27-guage needle for 25 times. The homogenate was incubated on ice for 30 
minutes, and then centrifuged at 16,000 g for 20 minutes at 4
o
C. The insoluble pellets (detergent-
resistant fraction) were resuspended in 40 μl SDS-PAGE sample buffer, and then 10 μl samples 
were loaded on SDS-PAGE gels for Western blots. Western blots were performed as previously 
described [19]. 
 
Real-time RT-PCR 
Cells were grown in triplicate on 12-well plates and treated as described in figure legends. Total 
RNA was harvested using TRI Reagent (Sigma-Aldrich), and reverse transcribed into cDNA 
using the SuperScript III First Strand cDNA Synthesis Kit (Life Technologies). mRNA levels 
were determined by qRT-PCR using SensiMix SYBR Green (Bioline) on a Corbett Rotorgene 
3000 (Corbett Life Sciences, Sydney, Australia) using primers for IQGAP1 (F: 
AAGAAGGCATATCAAGATCGG, R: CCTCAGCATTGATGAGAGTC), ABCA1 [55], 
HMGCR [56] and the housekeeping gene, porphobilinogen deaminase, PBGD [55]. The mRNA 
expression levels were normalized to that of PBGD and made relative to the vehicle condition 
using the ΔΔCt method. 
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Statistical analysis 
Two-tailed statistical analysis was performed using the GraphPad Prism software, and p-value 
less than 0.05 was regarded as significant. Pair-wise comparison for positive or negative 
bioluminescence was performed using Fisher’s exact test. 
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Figure legends 
Figure 1. Diet-induced hypercholesterolemia promotes androgen-independent prostate 
cancer metastasis but not primary tumor growth. (a) Experimental plan. Fourteen days prior 
to xenografting, mice were randomly allocated to low-cholesterol normal diet (LC-D, n = 14) or 
to a hypercholesterolemic diet (HC-D, n = 15). On day 0, human prostate cancer PC-3 expressing 
the luciferase gene were orthotopically injected into the dorsolateral prostate glands of male 
NOD/SCID mice. (b) Serum cholesterol, (c) body weight and (d and e) primary tumor growth 
was measured on the indicated days during the course of the experiment. (f) At the end of the 
experiment, primary prostate tumors were weighed after removing seminal vesicles and the 
urinary bladder. Ex vivo imaging was used to measure metastasis in (g) para-aortic lymph node 
(P-LN), (h) mesenteric lymph node (M-LN), (i) lung, and (j) bone. Error bars show standard 
error of the mean. NS, not significant; *p < 0.05; **p < 0.005; ***p < 0.0005.  Group 
comparison in (j) used Fisher’s exact test, **p < 0.005. 
 
Figure 2. Diet-induced hypercholesterolemia is not associated with increased angiogenesis, 
lymphangiogenesis, and circulating testosterone levels. (a) Representative images show 
double immunofluorescence staining of tumor tissue sections using the panendothelial cell 
marker endomucin (red) and the lymphatic specific marker podoplanin (green) Bar, 200 μm. (b) 
Angiogenesis was not significantly different between hypercholesterolemic and control diet 
groups (p = 0.3297, n = 9 per group). (c) Immunostaining for lymphangiogenesis demonstrated 
no significant difference between the diet groups (p = 0.35, n = 9 per group). (d) Circulating 
testosterone level was measured at days 0 and 42 using a homogeneous time resolved 
fluorescence assay. Data were represented as mean ± SEM (**p < 0.005, ***p < 0.0005). (e) 
Histopathology using H&E tissue sections demonstrated tumor cells invading into the capsule of 
the testes (arrows, tumors) Bar, 100 μm. 
 
Figure 3. In vitro quantitative proteomics suggests IQGAP1 as a cholesterol-related 
candidate. (a) PC-3 transmigration assay was performed using cholesterol-deficient medium 
(CDM) or control FBS (Ctrl-FBS). (b) PC-3 proliferation was determined using Alamar Blue 
assay. (c) Experimental plan for in vitro quantitative proteomics study using stable isotope 
labeling by amino acids in cell culture (SILAC). (d) Total cellular cholesterol and (e) protein 
concentrations of whole cell lysates were measured. (f) Cholesterol treatment (5 μM for 5 hours) 
significantly altered 41 out of 441 proteins, based on a 1.5 fold difference and p-values less than 
0.05. (g) Top 10 protein candidates up-regulated by cholesterol treatment. Uniprot, UniProt 
Entry ID; Name, gene name; Ratio ± STD, cholesterol(heavy)/control(light) SILAC ratio ± 
standard deviation; Adj. p-value, permutation p-value adjusted for multiple testing. (h) 
Immunoblotting of tumor lysates show that expression levels of IQGAP1 and caveolin-1 were 
significantly increased in HC-D group (n = 9 per group). (i) PC-3 cells were incubated with 5 
μM cholesterol or vehicle for 5 hours. Total cell lysates (20 μg) were separated on SDS-PAGE 
and immunoblotted with antibodies against IQGAP1, caveolin-1 and β-actin as indicated. 
IQGAP1 but not caveolin-1 was significantly altered by short-term cholesterol treatment. (j) 
Intratumoral cholesterol levels was measured in tumor lysates using Amplex Red cholesterol 
assay (n = 9 per group). Error bars show standard error of the mean; NS, not significant ; *p < 
0.05; **p < 0.005. 
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Figure 4. Cholesterol regulates IQGAP1 targeting to detergent-resistant fractions. (a) 
Relative expression of IQGAP1 and caveolin-1 in prostate cancer cell lines. Total cell lysates (20 
μg) from PC-3, LNCaP, 22Rv1 and DU145 were resolved on SDS-PAGE and immunoblotted 
for IQGAP1 and caveolin-1. Loading control: Coomassie staining. (b) Cholesterol treatment for 
5 hours does not alter caveolin-1 or IQGAP1 transcription as measured by qRT-PCR. (c) 
Immunofluorescence labeling for IQGAP1 (red) and staining for cholesterol using Filipin III 
(blue) in PC-3 cells, after treatment with 5 μM cholesterol or vehicle for 20 hours. Arrows, 
membrane ruffles enriched in cholesterol and IQGAP1. Bars, 10 μm. (d) IQGAP1 levels in 
detergent-resistant fractions (DRF) was examined in PC-3 cells (n = 3). (e) Immunofluorescence 
co-labeling for caveolin-1 and IQGAP1 in PC-3 cells after 20 hour treatment with 5 μM 
cholesterol or vehicle.  Bars, 10 μm. (f) DRF was collected from equal numbers of caveolin-1 
knockdown (shCav1) and control scrambled sequence knockdown (Scr) PC-3 cells. Equivalent 
volumes of DRF were separated by SDS-PAGE and immunoblotted for IQGAP1, flotillin-1 or 
caveolin-1. n = 3. Error bars show standard error of the mean; NS, not significant; *p < 0.05. 
Veh, vehicle; Chol, cholesterol. 
 
Figure 5. Knockdown of IQGAP1 and/or caveolin-1 in PC-3 cells reduces migration and 
invasion in vitro. PC-3-luciferase cell lines with reduced expression of IQGAP1 (shIQGAP1), 
caveolin-1 (shCav1) and both (shIQ+shCav) were generated using lentiviral-mediated shRNA. 
(a) Relative protein expression of IQGAP1 and caveolin-1 was measured by immunoblotting and 
quantified over 3 experiments. (b) Transmigration, (c) Matrigel invasion and (d) proliferation 
assays were performed for PC-3 stable cell lines. Error bars show standard error of the mean. **p 
< 0.005, ***p < 0.0005.  
 
Figure 6. Knockdown of IQGAP1 and/or caveolin-1 suppressed hypercholesterolemia-
induced prostate cancer metastasis. In vivo metastasis was assayed for shIQGAP1, shCav1 and 
shIQ+shCav1 PC-3-luciferase cells in HC-D intraprostatic xenograft model. (a and b) Real-time 
xenografted primary prostate tumor growth was monitored using whole body in vivo 
bioluminescence. Scrambled control (Scr-Ctrl, n = 10), IQGAP1 knockdown (shIQGAP1, n = 
11), caveolin-1 knockdown (shCav1, n = 11), and double knockdown of IQGAP1 and caveolin-1 
(shIQ+shCav1, n = 10). (c) Final prostate tumor weight was assessed after removing seminal 
vesicles and urinary bladder. Representative figures are shown (Bar, 10 mm). (d) The size of 
para-aortic lymph nodes was measured. (e) Representative figures show ex vivo bioluminescence 
imaging for para-aortic lymph nodes (P-LN) and the lung tissues.  Ex vivo bioluminescence was 
measured for secondary metastases in (f) para-aortic lymph nodes, (g) lung and (h) bone. Error 
bars show standard error of the mean. NS, not significant; *p < 0.05, **p < 0.005, ***p < 
0.0005. 
 
 
 






